Strategic application domain: Biotech - Pharma
Type of activity: CRO - Tools - R&D platform
Technologies: Antibodies - Protein - Peptide, Design & Modelling studies
The IMABGEN (Innovative Monoclonal AntiBody/antiGEN) platform aims at producing such antibodies with unparalleled completeness and efficiency by developing two axes.
The first will provide ‘native’ membrane antigens, which are both the most numerous and the most fragile targets, thanks to CALIXAR’s proprietary technologies and the expertise of two teams from the Molecular Microbiology and Structural Biochemistry Unit* (CNRS/Université Claude Bernard Lyon 1). Six antigens will thus be isolated, including receptors, transporters and synthases.
The second axis, carried out by BIOTEM, will generate new synthetic libraries with very broad spectrum, associated with a novel method of antibody selection.
RD Booster
RD Booster 2021
2021
regional project
On going
Duration: 24 months
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.